Please login to the form below
SOBI
This page shows the latest SOBI news and features for those working in and with pharma, biotech and healthcare.
Sobi’s Gamifant receives final rejection from CHMP for primary HLH
Sobi requested that the CHMP re-examine the application for Gamifant (emapalumab) as a treatment for of primary haemophagocytic lymphohistiocytosis (HLH) after the Committee initially rejected the drug in July. ... In the US, over 100 primary HLH
Latest news
-
GSK’s anti-BCMA drug leads crowded CHMP recommendations
Sobi has said it plans to request a re-examination by the CHMP and expects a subsequent opinion by the end of the year. ... The product has been able to make a substantial difference for a very vulnerable group of patients in the US,” said Guido Oelkers
-
Sobi set to spend up to $915m to acquire Dova Pharmaceuticals
Hopes to boost haematology franchise with lead drug Doptelet. Dova Pharmaceuticals is set to be acquired by Swedish Orphan Biovitrum AB (Sobi) for up to $915m, dependent on the regulatory approval ... Under the terms of the agreement, Sobi will offer a
-
FDA approves Bavarian Nordic’s smallpox and monkeypox vaccine
Earlier this year, AstraZeneca picked up a PRV from Sobi for $95m.
-
AstraZeneca buys FDA priority review voucher from Sobi
Picks up coveted voucher for $95m. AstraZeneca has paid Swedish biopharma company Sobi $95m in cash for an FDA priority review voucher (PRV), which could help cut four months off the ... Sobi gained the PRV during the acquisition of Novimmune’s
-
Sobi takes ownership of rare disease drug Gamifant for $518m
deal. “The acquisition of emapalumab and related assets is an important step in the transformation of Sobi in becoming a global leader in rare diseases,” says Guido Oelkers. ... We look forward to welcoming our new colleagues to join us in this
GSK’s anti-BCMA drug leads crowded CHMP recommendations
Sobi set to spend up to $915m to acquire Dova Pharmaceuticals
FDA approves Bavarian Nordic’s smallpox and monkeypox vaccine
AstraZeneca buys FDA priority review voucher from Sobi
More from news
Approximately 12 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Heggie has lots of experience in the rare disease field, having served in senior roles at Shire, as a board member at Sobi and as CEO of German rare disease biotech
-
A rare opportunity
Sobi’s Neil Dugdale on how the UK’s approach to rare diseases is changing. ... An exciting time. For Neil's company Sobi it's certainly been a busy time this year.
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
A rare opportunity
More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest appointments
-
New hires at FibroGen, Saniona and Turbine
Most recently, Levin worked as the president of Sobi, where he was responsible for building the organisation and developing the strategic growth pillars of the company. ... Prior to Sobi, Levin held commercial leadership roles of increasing strategic
-
BMS appoints new commercial leader, Davies joins Eisai and more
Sobi appoints head of technical operations. Rare disease specialist company Sobi has appointed Anne Marie de Jonge Schuermans to front its new technical operations organisation. ... operations. She joins Sobi from Biogen, where she served as vice
-
Sobi poaches Pfizer’s Fredrick Wetterlundh
Swedish Orphan Biovitrum (Sobi) has appointed Fredrik Wetterlundh as head of human resources and will simultaneously be part of Sobi’s extended leadership team. ... Guido Oelkers, CEO and president of Sobi, said: “His experience from the
-
Mereo BioPharma appoints head of patient access and commercial planning
Wills Hughes-Wilson joins the group from Sobi. London, UK-based Mereo BioPharma, has strengthened its team with the addition of Wills Hughes-Wilson, who joins the biopharma as its new ... In this role, Hughes-Wilson was responsible for Sobi’s
-
Sobi names Holly May VP of sales and marketing, US
Rare disease firm Sobi has appointed Holly May as its new vice president of sales and marketing for the US. ... May’s new role will see her lead the biopharma’s commercial team in bringing Sobi’s medicines to the country.
New hires at FibroGen, Saniona and Turbine
BMS appoints new commercial leader, Davies joins Eisai and more
Sobi poaches Pfizer’s Fredrick Wetterlundh
Mereo BioPharma appoints head of patient access and commercial planning
Sobi names Holly May VP of sales and marketing, US
More from appointments
Approximately 9 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
The RARE Youth Revolution has begun
LifeArc. Sobi. “We are a proud supporter of RARE Youth Revolution and we are absolutely thrilled to have them as part of the Breaking Down Barriers project!
-
Say Communications
Novo Nordisk. Nutricia. Nutricia Global. SOBI. Target Ovarian Cancer. Trudell Medical.
The RARE Youth Revolution has begun
Say Communications
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
-
Digital account director
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital project manager
-
Competitive
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- GSK reveals plans for £400m R&D facility expansion in England
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- Amgen signs $180m nanotechnology cancer deal
- British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- AZ’s comeback drug cediranib stumbles in phase 3 trial
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
